Current Clinical Practice: Current Therapeutic Options in Myelodysplastic Syndromes

References

• Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R. and Sultan, C. (1982). Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 51, 189–199.
   PubMed Web of Science ®Google Scholar
• Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G. and Schneider, W. (1992). Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia, 6, 52–59.
   PubMed Web of Science ®Google Scholar
• Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J. and Machin, D. (1985). Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol, 59, 425–433.
   PubMed Web of Science ®Google Scholar
• Sanz, G. F., Sanz, M. A., Vallespi, T., Canizo, M. C., Torrabadella, M., Garcia, S., Irriguible, D. and San Miguel, J. F. (1989). Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood, 74, 395–408.
   PubMed Web of Science ®Google Scholar
• Varela, B. L., Chuang, C., Woll, J. E. and Bennett, J. M. (1985). Modifications in the classification of primary myelodysplastic syndromes: the addition of a scoring system. Hematol Oncol, 3, 55–63.
   PubMed Web of Science ®Google Scholar
• Worsley, A., Oscier, D. G., Stevens, J., Darlow, S., Figes, A., Mufti, G. J. and Hamblin, T. J. (1988). Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol, 68, 17–21.
   PubMed Web of Science ®Google Scholar
• Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. and Bennett, J. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079–2088.
   PubMed Web of Science ®Google Scholar
• Aul, C., Bowen, D. T. and Yoshida, Y. (1998). Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica, 83, 71–86.
   PubMed Web of Science ®Google Scholar
• Ribera, J. M., Cervantes, F. and Rozman, C. (1987). A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. Br J Haematol, 65, 307–311.
   PubMed Web of Science ®Google Scholar
• Tester, W. J., Kinsella, T. J, Waller, B., Makuch, R. W., Kelley, P. A., Glatstein, E. and DeVita, V. T. (1984). Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol, 2, 762–769.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M. and Keating, M. J. (1987). Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol, 14, 435–443.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., Estey, E. H. and Keating, M. J. (1993). Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am, 7, 81–107.
   PubMed Web of Science ®Google Scholar
• Miller, J. S., Arthur, D. C., Litz, C. E., Neglia, J. P., Miller, W. J. and Weisdorf, D. J. (1994). Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood, 83, 3780–3786.
   PubMed Web of Science ®Google Scholar
• Stone, R. M., Bernstein, S. H., Demetri, G., Facklam, D. P., Arthur, K., Andersen, J., Aster, J. C. and Kufe, D. (1994). Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res, 18, 769–776.
   PubMed Web of Science ®Google Scholar
• Stone, R. M., Neuberg, D., Soiffer, R., Takvorian, T., Whelan, M., Rabinowe, S. N., Aster, J. C., Leavitt, P., Mauch, P. and Freedman, A. S. (1994). Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol, 12, 2535–2542.
   PubMed Web of Science ®Google Scholar
• Parker, J. E. and Mufti, G. J. (1998). Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol, 101, 220–230.
   PubMed Web of Science ®Google Scholar
• Parker, J. and Mufti, G. J. (1996). Ras and myelodysplasia: lessons from the last decade. Semin Hematol, 33, 206–224.
   PubMed Web of Science ®Google Scholar
• Seipelt, G., Ganser, A., Duranceyk, H., Maurer, A., Ottmann, O. G. and Hoelzer, D. (1993). Induction of TNF-alpha in patients with myelodysplastic syndromes undergoing treatment with interleukin-3. Br J Haematol, 84, 749–751.
   PubMed Web of Science ®Google Scholar
• Hofmann, W. K., Kalina, U., Wagner, S., Seipelt, G., Ries, C., Hoelzer, D. and Ottmann, O. G. (1999). Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. Exp Hematol, 27, 395–400.
   PubMed Web of Science ®Google Scholar
• Fenaux, P., Morel, P. and Lai, J. L. (1996). Cytogenetics of myelodysplastic syndromes. Semin Hematol, 33, 127–138.
   PubMed Web of Science ®Google Scholar
• Mufti, G. J. (1992). Chromosomal deletions in the myelodysplastic syndrome. Leuk Res, 16, 35–41.
   PubMed Web of Science ®Google Scholar
• Hofmann, W. K., Ottmann, O. G., Ganser, A. and Hoelzer, D. (1996). Myelodysplastic syndromes: clinical features. Semin Hematol, 33, 177–185.
   PubMed Web of Science ®Google Scholar
• Appelbaum, F. R. and Anderson, J. (1998). Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia, 12(1), S25–S29.
   PubMedGoogle Scholar
• Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. and Or, R. (1998). Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91, 756–763.
   PubMed Web of Science ®Google Scholar
• Arnold, R., de Witte, T., van Biezen, A., Hermans, J., Jacobsen, N., Runde, V., Gratwohl, A. and Apperley, J. F. (1998). Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant, 21, 1213–1216.
   PubMed Web of Science ®Google Scholar
• de Witte, T., van Biezen, A., Hermans, J., Labopin, M., Runde, V., Or, R., Meloni, G., Mauri, S. B., Carella, A., Apperley, J., Gratwohl, A. and Laporte, J. P. (1997). Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood, 90, 3853–3857.
   PubMed Web of Science ®Google Scholar
• Boogaerts, M. A. (1998). Stem cell transplantation and intensified cytotoxic treatment for myelodysplasia. Curr Opin Hematol, 5, 465–471.
   PubMedGoogle Scholar
• Delforge, M., Demuynck, H., Verhoef, G., Vandenberghe, P., Zachee, P., Maertens, J., Van Duppen, V. and Boogaerts, M. A. (1998). Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete hematological remission. Br J Haematol, 102, 486–494.
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg, E. (1995). Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol, 89, 67–71.
   PubMed Web of Science ®Google Scholar
• Greenberg, P., Taylor, K., Larson, R., Koeffler, P., Negrin, R., Saba, H., Ganser, A., Jakubowski, A., Gabrilove, J., Mufti, G., Cruz, J., Hammond, W., Broudy, V., Langley, G. R., Keating, A., Vardiman, J., Lamborn, K. and Brown, S. (1993). Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Blood, 82(1), 196a.
   Google Scholar
• Fleischmann, J., Golde, D. W., Weisbart, R. H. and Gasson, J. C. (1986). Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood, 68, 708–711.
   PubMed Web of Science ®Google Scholar
• Gordon, M. S., Nemunaitis, J., Hoffman, R., Paquette, R. L., Rosenfeld, C., Manfreda, S., Isaacs, R. and Nimer, S. D. (1995). A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood, 85, 3066–3076.
   PubMed Web of Science ®Google Scholar
• Adams, J. A., Liu Yin, J. A., Brereton, M. L., Briggs, M., Burgess, R. and Hyde, K. (1997). The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryopoiesis in normal subjects and patients with myelodysplasia and acute myeloid leukaemia. Br J Haematol, 99, 139–146.
   PubMed Web of Science ®Google Scholar
• Gallagher, R. E., Lurie, K. J., Leavitt, R. D. and Wiernik, P. H. (1987). Effects of interferon and retinoic acid on the growth and differentiation of clonogenic leukemic cells from acute myelogenous leukemia patients treated with recombinant leukocyte-alpha A interferon. Leuk Res, 11, 609–619.
   PubMed Web of Science ®Google Scholar
• Buessow, S. C. and Gillespie, G. Y. (1984). Interferon-alpha and -gamma promote myeloid differentiation of HL-60, a human acute promyelocytic leukemia cell line. J Biol Response Mod, 3, 653–662.
   PubMedGoogle Scholar
• Hoffman, S. J. and Robinson, W. A. (1988). Use of differentiation-inducing agents in the myelodysplastic syndrome and acute non-lymphocytic leukemia. Am J Hematol, 28, 124–127.
   PubMed Web of Science ®Google Scholar
• Hast, R., Beksac, M., Axdorph, S., Sjogren, A. M., Ost, A. and Reizenstein, P. (1986). Effects of retinoids on in vitro differentiation of bone marrow cells in the myelodysplastic syndrome. Med Oncol Tumor Pharmacother, 3, 35–38.
   PubMedGoogle Scholar
• Fabian, I., Shvartzmayer, S. and Nagler, A. (1987). In-vitro growth and differentiation of marrow cells from myelodysplastic patients in the presence of a retinoidal benzoic acid derivative. Leuk Res, 11, 635–640.
   PubMed Web of Science ®Google Scholar
• Gallagher, R. E., Said, F., Pua, I., Papenhausen, P. R., Paietta, E. and Wiernik, P. H. (1989). Expression of retinoic acid receptor-alpha mRNA in human leukemia cells with variable responsiveness to retinoic acid. Leukemia, 3, 789–795.
   PubMed Web of Science ®Google Scholar
• Gallagher, R. E., de Cuevillas, F., Chang, C. S. and Schwartz, E. L. (1989). Variable regulation of sensitivity to retinoic acid-induced differentiation in wild-type and retinoic acid-resistant HL-60 cells. Cancer Commun, 1, 45–54.
   PubMedGoogle Scholar
• Santini, V. and Ferrini, P. R. (1998). Differentiation therapy of myelodysplastic syndromes: fact or fiction? Br J Haematol, 102, 1124–1138.
   PubMed Web of Science ®Google Scholar
• Ganser, A., Seipelt, G., Verbeek, W., Ottmann, O. G., Maurer, A., Kolbe, K., Hess, U., Elsner, S., Reutzel, R. and Wormann, B. (1994). Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia, 8, 369–375.
   PubMed Web of Science ®Google Scholar
• Ganser, A., Maurer, A., Contzen, C., Seipelt, G., Ottmann, O. G., Schadeck-Gressel, C., Kolbe, K., Haas, R., Zander, C., Reutzel, R. and Hoelzer, D. (1996). Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Ann Hematol, 71, 237–244.
   Google Scholar
• Hofmann, W. K., Ganser, A., Seipelt, G., Ottmann, O. G., Zander, C., Geiβler, G., Hoffmann, K., Höffken, K., Fischer, J. Th., Isele, G. and Hoelzer, D. (1999). Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol, 78, 125–130.
   PubMed Web of Science ®Google Scholar
• Abe, E., Miyaura, C., Sakagami, H., Takeda, M., Konno, K., Yamazaki, T., Yoshiki, S. and Suda, T. (1981). Differentiation of mouse myeloid leukemia cells induced by 1 alpha, 25-dihydroxyvitamin D3. Proc Natl Acad Sci USA, 78, 4990–4994.
   PubMed Web of Science ®Google Scholar
• Tanaka, H., Abe, E., Miyaura, C., Kuribayashi, T., Konno, K., Nishii, Y. and Suda, T. (1982). 1 alpha, 25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). Biochem J, 204, 713–719.
   PubMed Web of Science ®Google Scholar
• Mehta, A. B., Kumaran, T. O., Marsh, G. W. and Mc-Carthy, D. M. (1984). Treatment of advanced myelodysplastic syndrome with alfacalcidol. Lancet, 2, 761.
   PubMed Web of Science ®Google Scholar
• Koeffler, H. P., Hirji, K. and Itri, L. (1985). 1,25-Dihydroxy-vitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep, 69, 1399–1407.
   PubMedGoogle Scholar
• Richard, C., Mazo, E., Cuadrado, M. A., Iriondo, A., Bello, C., Gandarillas, M. A. and Zubizarreta, A. (1986). Treatment of myelodysplastic syndrome with 1,25-dihydroxy-vitamin D3. Am J Hematol, 23, 175–178.
   PubMed Web of Science ®Google Scholar
• Motomura, S., Kanamori, H., Maruta, A., Kodama, F. and Ohkubo, T. (1991). The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol, 38, 67–68.
   PubMed Web of Science ®Google Scholar
• Mellibovsky, L., Diez, A., Aubia, J., Nogues, X., Perez-Vila, E., Serrano, S. and Recker, R. R. (1993). Long-standing remission after 25-OH D3 treatment in a case of chronic myelomonocytic leukaemia. Br J Haematol, 85, 811–812.
   PubMed Web of Science ®Google Scholar
• Hellstrom, E., Robert, K. H., Gahrton, G., Mellstedt, H., Lindemalm, C., Einhorn, S., Bjorkholm, M., Grimfors, G., Uden, A. M. and Samuelsson, J. (1988). Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes. Eur J Haematol, 40, 449–459.
   PubMed Web of Science ®Google Scholar
• Hellstrom, E., Robert, K. H., Samuelsson, J., Lindemalm, C., Grimfors, G., Kimby, E., Oberg, G., Winqvist, I., Billstrom, R. and Carneskog, J. (1990). Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha- hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). Eur J Haematol, 45, 255–261.
   PubMed Web of Science ®Google Scholar
• Ferrero, D., Bruno, B., Pregno, P., Stefani, S., Larizza, E., Ciravegna, G., Luraschi, A., Vietti-Ramus, G., Schinco, P., Bazzan, M., Gallo, E. and Pileri, A. (1996). Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Leuk Res, 20, 867–876.
   PubMed Web of Science ®Google Scholar
• Rowinsky, E. K., Donehower, R. C., Spivak, J. L., Burke, P. J., Griffin, C. A. and Jones, R. J. (1990). Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors. J Natl Cancer Inst, 82, 1926–1931.
   PubMedGoogle Scholar
• Rowinsky, E. K., Conley, B. A., Jones, R. J., Spivak, J. L., Auerbach, M. and Donehower, R. C. (1992). Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. Leukemia, 6, 526–534.
   PubMed Web of Science ®Google Scholar
• Andreeff, M., Stone, R., Michaeli, J., Young, C. W., Tong, W. P., Sogoloff, H., Ervin, T., Kufe, D., Rifkind, R. A. and Marks, P. A. (1992). Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood, 80, 2604–2609.
   PubMed Web of Science ®Google Scholar
• Christman, J. K., Mendelsohn, N., Herzog, D. and Schneiderman, N. (1983). Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res, 43, 763–769.
   PubMed Web of Science ®Google Scholar
• Cihak, A. (1974). Biological effects of 5-azacytidine in eukaryotes. Oncology, 30, 405–422.
   PubMed Web of Science ®Google Scholar
• Jones, P. A. and Taylor, S. M. (1980). Cellular differentiation, cytidine analogs and DNA methylation. Cell, 20, 85–93.
   PubMed Web of Science ®Google Scholar
• Silverman, L. R., Holland, J. F., Weinberg, R. S., Alter, B. P., Davis, R. B., Ellison, R. R., Demakos, E. P., Cornell, C. J., Jr., Carey, R. W. and Schiffer, C. (1993). Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia, 7(1), 21–29.
   PubMedGoogle Scholar
• Zagonel, V., Lo Re, G., Marotta, G., Babare, R., Sardeo, G., Gattei, V., De Angelis, V., Monfardini, S. and Pinto, A. (1993). 5-Aza-2′-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia, 7(1), 30–35.
   PubMedGoogle Scholar
• Gore, S. D., Samid, D. and Weng, L. J. (1997). Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res, 3, 1755–1762.
   PubMed Web of Science ®Google Scholar
• Leder, A., Orkin, S. and Leder, P. (1975). Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis. Science, 190, 893–894.
   PubMed Web of Science ®Google Scholar
• Santini, V., Scappini, B., Gozzini, A., Grossi, A., Villa, P., Ronco, G., Douillet, O., Pouillart, P., Bernabei, P. A. and Rossi Ferrini, P. (1998). Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells. Br J Haematol, 101, 529–538.
   PubMed Web of Science ®Google Scholar
• Pouillart, P., Douillet, O., Scappini, B., Gozzini, A., Santini, V., Grossi, A., Pagliai, G., Strippoli, P., Rigacci, L., Ronco, G. and Villa, P. (1999). Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from D-mannose and xylitol: influence of alkyl chain length on acute toxicity. Eur J Pharm Sci, 7, 93–106.
   PubMed Web of Science ®Google Scholar
• Gore, S. D., Miller, C. B., Weng, L. J., Burks, K., Griffin, C. A., Chen, T. L., Smith, V., Birke, P. J., Grever, M. and Rowinsky, E. K. (1997). Clinical development of sodium phenylbutyrate as a putative differentiating agent in myeloid malignancies. Anticancer Res, 17, 3938a.
   Google Scholar
• List, A. F., Heaton, R., Glinsmann-Gibson, B. and Capizzi, R. L. (1996). Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol, 23, 58–63.
   PubMed Web of Science ®Google Scholar
• Glover, D., Glick, J. H., Weiler, C., Hurowitz, S. and Kligerman, M. M. (1986). WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol, 4, 584–588.
   PubMed Web of Science ®Google Scholar
• Kemp. G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D. and Glick, J. (1996). Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer, J Clin Oncol, 14, 2101–2112.
   PubMed Web of Science ®Google Scholar
• List, A. F., Brasfield, F., Heaton, R., Glinsmann-Gibson, B., Crook, L., Taetle, R. and Capizzi, R. (1997). Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood, 90, 3364–3369.
   PubMed Web of Science ®Google Scholar
• deCastro, C. M., Glockerman, J. P., Moore, J. O., Hartung, C. and Misuraca, J. (1998). Treatment of myelodysplastic syndromes (MDS) with amifostine. Blood, 92(1), 251b.
   Google Scholar
• Grossi, A., Fabbri, A., Santini, V., Longo, G., Leoni, F., Vannucchi, A. M., Pagliai, G., Rossi-Ferrini, P. and Morfini, M. (1998). Amifostine as a single agent or in combination regimen with low-dose ARA-C in the treatment of myelodysplastic syndromes. Blood, 92(1), 632a.
   PubMedGoogle Scholar
• Raza, A., Qawi, H., Naseer, O. B., Dar, S., Lisak, L., Andric, T., Ali, S. I., Quadri, M., Ahmed, P., Venugopal, P., Gezer, S., Gregory, S., Loew, J., Robin, E. and Rifkin, S. (1998). Cytopenias improve in response to amifostine pentoxifylline/ciprofloxacin/dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS). Blood, 92(1), 631a.
   Google Scholar
• Schuster, S. J., Crook, A., Mathews, A., Tsai, D., Vala, M., Kocher, W., Filicko, J. and Capizzi, R. L. (1998). Crossover trial of subcutaneous versus intravenous amifostine in patients with de novo myelodysplastic syndromes: preliminary results. Blood, 92(1), 362a.
   PubMedGoogle Scholar
• Champlin, R., Ho, W. and Gale, R. P. (1983). Anti-thymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med, 308, 113–118.
   PubMed Web of Science ®Google Scholar
• Young, N., Griffith, P., Brittain, E., Elfenbein, G., Gardner, F., Huang, A., Harmon, D., Hewlett, J., Fay, J. and Mangan, K. (1988). A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood, 72, 1861–1869.
   PubMed Web of Science ®Google Scholar
• Frickhofen, N., Kaltwasser, J. P., Schrezenmeier, H., Raghavachar, A., Vogt, H. G., Herrmann, F., Freund, M., Meusers, P., Salama, A. and Heimpel, H. (1991). Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med, 324, 1297–1304.
   PubMed Web of Science ®Google Scholar
• Frickhofen, N. and Kaltwasser, J. P. (1988). Immuno-suppressive treatment of aplastic anemia: a prospective, randomized multicenter trial evaluating antilymphocyte globulin (ALG) versus ALG and cyclosporin A. Blut, 56, 191–192.
   PubMedGoogle Scholar
• Mineishi, S., Filippa, D., Childs, B. and Castro-Mala-spina, H. (1994). Hypoplastic myelodysplastic syndrome (MDS): clinical, hematologic, and pathologic observations in 36 cases. Blood, 84(1), 315a.
   PubMedGoogle Scholar
• Sulecki, M., Shadduck, R. K. and Zeigler, Z. (1988). Anti-thymocyte globulin for hypoplastic myelodysplastic snydrome. Blood, 72(1), 229a.
   Google Scholar
• Tichelli, A., Gratwohl, A., Wuersch, A., Nissen, C. and Speck, B. (1988). Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol, 68,139–140.
   PubMed Web of Science ®Google Scholar
• Molldrem, J. J., Caples, M., Mavroudis, D., Plante, M., Young, N. S. and Barrett, A. J. (1997). Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol, 99, 699–705.
   PubMed Web of Science ®Google Scholar
• Molldrem, J., Caples, M., Mavroudis, D., Young, N. S. and Barrett, A. J. (1997). Treatment with antithymocyte globulin (ATG) induces sustained transfusion independence in patients with refractory anemia and myelodyplastic syndromes. Blood, 90(1), 84a.
   Google Scholar
• Marsh, J. C. and Gordon-Smith, E. C. (1995). Treatment of aplastic anaemia with antilymphocyte globulin and cyclosporin. Int J Hematol, 62, 133–144.
   PubMed Web of Science ®Google Scholar
• Porta, F., Facchetti, F., Tettoni, K., Laffranchi, M. G., Arrighini, A. and Ugazio, A. G. (1998). Myelodysplastic syndrome in an infant: induction of remission by cyclosporin. Lancet, 352, 1600–1601.
   PubMed Web of Science ®Google Scholar
• Biesma, D. H., van den Tweel, J. G. and Verdonck, L. F. (1997). Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer, 79, 1548–1551.
   PubMed Web of Science ®Google Scholar
• Jonasova, A., Neuwirtova, R., Cermak, J., Vozobulova, V., Mocikova, K., Siskova, M. and Hochova, I. (1998). Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol, 100, 304–309.
   PubMed Web of Science ®Google Scholar
• Parovitchnikova, E., Savchenko, V., Mikhailova, E., Kokhno, A., Olshanskaya, Y., Tzvetaeva, N., Lapin, V., Obidina, N., Gribanova, E., Ustinova, E., Tikhonova, L. and Frank, G. (1998). Cyclosporin A may be effective in different forms of myelodysplastic syndromes. Blood, 92(1), 633a.
   Google Scholar
• Hofmann, W. K., Ganser, A., Ottmann, O. G., Seipelt, G., Zander, C., Fischer, J. Th., Höffken, K., Hoffmann, K. and Hoelzer, D. (1998). Long-term complete remissions in patients with low-risk myelodysplastic syndromes during combination treatment using all-trans retinoic acid. Br J Haematol, 102(1), 343.
   Web of Science ®Google Scholar
• Cheson, B. D. (1998). Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res, 22(1), S17–21.
   PubMed Web of Science ®Google Scholar
• Cheson, B. D. and Simon, R. (1987). Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. Semin Oncol, 14, 126–133.
   PubMed Web of Science ®Google Scholar
• Miller, K. B., Kim, K., Morrison, F. S., Winter, J. N., Bennett, J. M., Neiman, R. S., Head, D. R., Cassileth, P. A. and O'Connell, M. J. (1992). The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol, 65, 162–168.
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg, E., Robert, K. H., Gahrton, G., Lindberg, G., Forsblom, A. M., Kock, Y. and Ost, A. (1992). A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br J Haematol, 81, 503–511.
   PubMed Web of Science ®Google Scholar
• Cines, D. B., Cassileth, P. A. and Kiss, J. E. (1985). Danazol therapy in myelodysplasia. Ann Intern Med, 103, 58–60.
   PubMed Web of Science ®Google Scholar
• Feldman, E., Seiter, D., Case, D., Plaza, F., Goff, H., Pozzuoli, M., Baskind, P., Fatora, R. and McMichael, J. (1998). Clinical evaluation of a commercial preparation of human chorionic gonadotropin (HCG) in myelodysplastic syndrome (MDS). Blood, 92(1), 632a.
   PubMedGoogle Scholar
• O'Donnell, M. R., Nademanee, A. P., Synder, D. S., Schmidt, G. M., Parker, P. M., Bierman, P. J., Fahey, J. L., Stein, A. S., Krance, R. A. and Stock, A. D. (1987). Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol, 5,1822–1826.
   PubMed Web of Science ®Google Scholar
• Longmore, G., Guinan, E. C., Weinstein, H. J., Gelber, R. D., Rappeport, J. M. and Antin, J. H. (1990). Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol, 8, 1707–1714.
   PubMed Web of Science ®Google Scholar
• de Witte, T., Zwaan, F., Hermans, J., Vernant, J., Kolb, H., Vossen, J., Lonnqvist, B., Beelen, D., Ferrant, A. and Gmur, J. (1990). Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol, 74, 151–155.
   PubMed Web of Science ®Google Scholar
• Sutton, L., Leblond, V., Le Maignan, C., Jouet, J. P., Kuentz, M., Gluckman, E., Blaise, D., Marit, G., Attal, M. and Troussard, X. (1991). Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: outcome of 86 patients. Bone Marrow Transplant, 7(2), 39.
   PubMedGoogle Scholar
• Nevill, T. J., Shepherd, J. D., Reece, D. E., Barnett, M. J., Nantel, S. H., Klingemann, H. G. and Phillips, G. L. (1992). Treatment of myelodysplastic syndrome with busulfancyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant, 10, 445–450.
   PubMed Web of Science ®Google Scholar
• Uberti, J. P., Ratanatharathorn, V., Karanes, C. and Sensenbrenner, L. L. (1994). Allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Leuk Lymphoma, 14, 379–385.
   PubMed Web of Science ®Google Scholar
• Demuynck, H., Verhoef, G. E., Zachee, P., Emonds, M. P., van der Schueren, E., van den Berghe, H., Vandenberghe, P., Casteels-Van Daele, M. and Boogaerts, M. A. (1996). Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant, 17, 745–751.
   PubMed Web of Science ®Google Scholar
• Ballen, K. K., Gilliland, D. G., Guinan, E. C., Hsieh, C. C., Parsons, S. K., Rimm, I. J., Ferrara, J. L., Bierer, B. E., Weinstein, H. J. and Antin, J.H. (1997). Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant, 20, 737–743.
   PubMed Web of Science ®Google Scholar
• Laporte, J. P., Isnard, F., Lesage, S., Fenaux, P., Douay, L., Lopez, M., Stachowiak, J., Najman, A. and Gorin, N. C. (1993). Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. Leukemia, 7, 2030–2033.
   PubMed Web of Science ®Google Scholar
• Stein, R. S., Abels, R. I. and Krantz, S. B. (1991). Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood, 78, 1658–1663.
   PubMed Web of Science ®Google Scholar
• Schouten, H. C., Vellenga, E., van Rhenen, D. J., de Wolf, J. T., Coppens, P. J. and Blijham, G. H. (1991). Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia, 5, 432–436.
   PubMed Web of Science ®Google Scholar
• Kurzrock, R., Talpaz, M., Estey, E., O'Brien, S., Estrov, Z. and Gutterman, J. U. (1991). Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia, 5, 985–990.
   PubMed Web of Science ®Google Scholar
• Razzano, M., Caslini, C., Cortelazzo, S., Battistel, V., Rambaldi, A. and Barbui, T. (1992). Therapy with human recombinant erythropoietin in patients with myelodysplastic syndromes. Br J Haematol, 81, 628–630.
   PubMed Web of Science ®Google Scholar
• Goy, A., Belanger, C., Casadevall, N., Picard, F., Guesnu, M., Jaulmes, D., Poisson, D. and Varet, B. (1993). High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. Br J Haematol, 84, 232–237.
   PubMed Web of Science ®Google Scholar
• Yoshida, Y., Anzai, N., Kawabata, H., Kohsaka, Y. and Okuma, M. (1993). Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment. Ann Hematol, 66, 175–180.
   PubMed Web of Science ®Google Scholar
• Zeigler, Z. R., Jones, D., Rosenfeld, C. S. and Shadduck, R. K. (1993). Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome. Stem Cells, 11, 49–55.
   PubMed Web of Science ®Google Scholar
• Stenke, L., Wallvik, J., Celsing, F. and Hast, R. (1993). Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia, 7, 1324–1327.
   PubMed Web of Science ®Google Scholar
• Aloe Spiriti, M. A., Petti, M. C., Latagliata, R., Avvisati, G., De Gregoris, C., Proia, S., Fazi, P., Jaalouk, G., Mancini, M. and Spadea, A. (1993). Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile? Leuk Lymphoma, 9, 79–83.
   PubMed Web of Science ®Google Scholar
• Isnard, F., Najman, A., Jaar, B., Fenaux, P., Baillou, C., Khoury, E., Labopin, M., Laporte, J. P., Woler, M. and Gorin, N. C. (1994). Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. Leuk Lymphoma, 12, 307–314.
   PubMed Web of Science ®Google Scholar
• Rose, E. H., Abels, R. I., Nelson, R. A., McCullough, D. M. and Lessin, L. (1995). The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol, 89, 831–837.
   PubMed Web of Science ®Google Scholar
• Kobayashi, Y., Okabe, T., Ozawa, K., Chiba, S., Hino, M., Miyazono, K., Urabe, A. and Takaku, F. (1989). Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report. Am J Med, 86, 178–182.
   PubMed Web of Science ®Google Scholar
• Ohyashiki, K., Ohyashiki, J. H., Toyama, K. and Takaku, F. (1989). Hematologic and cytogenetic findings in myelodysplastic syndromes treated with recombinant human granulocyte colony-stimulating factor. Jpn J Cancer Res, 80, 848–854.
   PubMedGoogle Scholar
• Negrin, R. S., Haeuber, D. H., Nagler, A., Olds, L. C., Donlon, T., Souza, L. M. and Greenberg, P. L. (1989). Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I–II trial. Ann Intern Med, 110, 976–984.
   PubMed Web of Science ®Google Scholar
• Negrin, R. S., Haeuber, D. H., Nagler, A., Kobayashi, Y., Sklar, J., Donlon, T., Vincent, M. and Greenberg, P. L. (1990). Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood, 76, 36–43.
   PubMed Web of Science ®Google Scholar
• Yoshida, Y. (1991). Interferon gamma induces differentiation of cells from patients with myelodysplastic syndromes in vitro and in vivo. Leukemia, 5, 796–798.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj, S., Keating, M., LeMaistre, A., Hittelman, W. N., McCredie, K., Trujillo, J. M., Broxmeyer, H. E., Henney, C. and Gutterman, J. U. (1987). Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med, 317, 1545–1552.
   PubMed Web of Science ®Google Scholar
• Thompson, J. A., Lee, D. J., Kidd, P., Rubin, E., Kaufmann, J., Bonnem, E.M. and Fefer, A. (1989). Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol, 7, 629–637.
   PubMed Web of Science ®Google Scholar
• Dunbar, C. E., Smith, D., Kimball, J., Garrison, L., Nienhuis, A. W. and Young, N. S. (1990). Sequential treatment with recombinant human growth factors to compare activity of GM-CSF and IL3 in the treatment of primary myelodysplasia. Blood, 76(1), 141a.
   Google Scholar
• Rosenfeld, C. S., Sulecki, M., Evans, C. and Shadduck, R. K. (1991). Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia. Exp Hematol, 19, 273–277.
   PubMed Web of Science ®Google Scholar
• Estey, E. H., Kurzrock, R., Talpaz, M., McCredie, K. B., O'Brien, S., Kantarjian, H. M., Keating, M. J., Deisseroth, A. B. and Gutterman, J. U. (1991). Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol, 77, 291–295.
   PubMed Web of Science ®Google Scholar
• Willemze, R., van der Lely, N., Zwierzina, H., Suciu, S., Solbu, G., Gerhartz, H., Labar, B., Visani, G., Peetermans, M. E. and Jacobs, A. (1992). A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. Ann Hematol, 64, 173–180.
   PubMed Web of Science ®Google Scholar
• Takahashi, M., Yoshida, Y., Kaku, K., Masaoka, T., Moriyama, Y., Nakanishi, S., Kaneko, T., Shibata, A. and Miwa, S. (1993). Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia. Acta Haematol, 89, 189–194.
   PubMed Web of Science ®Google Scholar
• Rose, C., Wattel, E., Bastion, Y., Berger, E., Bauters, F., Coiffier, B. and Fenaux, P. (1994). Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. Leukemia, 8, 1458–1462.
   PubMed Web of Science ®Google Scholar
• Yoshida, Y., Nakahata, T., Shibata, A., Takahashi, M., Moriyama, Y., Kaku, K., Masaoka, T., Kaneko, T. and Miwa, S. (1995). Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome. Leuk Lymphoma, 18, 457–463.
   PubMed Web of Science ®Google Scholar
• Ganser, A., Seipelt, G., Lindemann, A., Ottmann, O. G., Falk, S., Eder, M., Herrmann, F., Becher, R., Hoffken, K. and Buchner, T. (1990). Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood, 76, 455–462.
   PubMed Web of Science ®Google Scholar
• Bernstein, S. H., Gilliland, D. G., Aster, J. C., Demetri, G. D., Merica, E. A., Shulman, L. N., Slapak, C. A., Vesper, D. and Stone, R. M. (1992). A randomized trial of two doses of recombinant human interleukin-3 (rh IL-3) in patients with myelodysplastic syndrome (MDS). Blood, 80(1), 410a.
   Google Scholar
• Ganser, A., Ottmann, O. G., Seipelt, G., Lindemann, A., Hess, U., Geissler, G., Maurer, A., Frisch, J., Schulz, G. and Mertelsmann, R. (1993). Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia, 7, 696–701.
   PubMed Web of Science ®Google Scholar
• Nimer, S. D., Paquette, R. L., Ireland, P., Resta, D., Young, D. and Golde, D. W. (1994). A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol, 22, 875–880.
   PubMed Web of Science ®Google Scholar
• Elias, L., Hoffman, R., Boswell, S., Tensen, L. and Bonnem, E. M. (1987). A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results. Leukemia, 1, 105–110.
   PubMed Web of Science ®Google Scholar
• Galvani, D. W., Cawley, J. C., Nethersell, A. and Bottomley, J. M. (1987). Alpha-interferon in myelodysplasia. Br J Haematol, 66, 145–146.
   PubMed Web of Science ®Google Scholar
• Maiolo, A. T., Cortelezzi, A., Calori, R. and Polli, E. E. (1990). Recombinant gamma-interferon as first line therapy for high risk myelodysplastic syndromes. Italian MDS Study Group. Leukemia, 4, 480–485.
   PubMed Web of Science ®Google Scholar
• Schwarzinger, I., Stain, C., Bettelheim, P., Hinterberger, W. and Lechner, K. (1990). Gamma-interferon in myelodysplastic syndromes: a pilot study. Oncology, 47, 322–326.
   PubMed Web of Science ®Google Scholar
• Gisslinger, H., Chott, A., Linkesch, W., Fritz, E. and Ludwig, H. (1990). Long-term alpha-interferon therapy in myelodysplastic syndromes. Leukemia, 4, 91–94.
   PubMed Web of Science ®Google Scholar
• Aul, C., Gattermann, N. and Schneider, W. (1991). Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b. Eur J Haematol, 46, 11–16.
   PubMed Web of Science ®Google Scholar
• Nand, S., Ellis, T., Messmore, H., Fisher, S. G., Gaynor, E. and Fisher, R. I. (1992). Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes. Leukemia, 6, 220–223.
   PubMed Web of Science ®Google Scholar
• Holcombe, R. F. (1993). Mini-dose interferon alpha-2a in the treatment of myelodysplasia. Leukemia, 7, 192–195.
   PubMed Web of Science ®Google Scholar
• Petti, M. C., Latagliata, R., Avvisati, G., Spiriti, M. A., Montefusco, E., Spadea, A. and Mandelli, F. (1996). Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferon. Br J Haematol, 95, 364–367.
   PubMed Web of Science ®Google Scholar
• Gold, E. J., Mertelsmann, R. H., Itri, L. M., Gee, T., Arlin, Z., Kempin, S., Clarkson, B. and Moore, M. A. (1983). Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. Cancer Treat Rep, 67, 981–986.
   PubMedGoogle Scholar
• Greenberg, B. R., Durie, B. G., Barnett, T. C. and Meyskens, F. L., Jr. (1985). Phase I–II study of 13-cis-retinoic acid in myelodysplastic syndrome. Cancer Treat Rep, 69, 1369–1374.
   PubMedGoogle Scholar
• Picozzi, V. J., Jr., Swanson, G. F., Morgan, R., Hecht, F. and Greenberg, P. L. (1986). 13-cis retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol, 4, 589–595.
   PubMed Web of Science ®Google Scholar
• Koeffler, H. P., Heitjan, D., Mertelsmann, R., Kolitz, J. E., Schulman, P., Itri, L., Gunter, P. and Besa, E. (1988). Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. Blood, 71, 703–708.
   PubMed Web of Science ®Google Scholar
• Leoni, F., Ciolli, S., Longo, G., Messori, A. and Ferrini, P. R. (1988). 13-cis-Retinoic acid treatment in patients with myelodysplastic syndrome. Acta Haematol, 80, 8–12.
   PubMed Web of Science ®Google Scholar
• Besa, E. C., Abrahm, J. L., Bartholomew, M. J., Hyzinski, M. and Nowell, P. C. (1990). Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alphatocopherol. Am J Med, 89, 739–747.
   PubMed Web of Science ®Google Scholar
• Bourantas, K. L., Tsiara, S. and Christou, L. (1995). Treatment of 34 patients with myelodysplastic syndromes with 13-CIS retinoic acid. Eur J Haematol, 55, 235–239.
   PubMed Web of Science ®Google Scholar
• Ohno, R., Naoe, T., Hirano, M., Kobayashi, M., Hirai, H., Tubaki, K. and Oh, H. (1993). Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Blood, 81, 1152–1154.
   PubMed Web of Science ®Google Scholar
• Aul, C., Runde, V. and Gattermann, N. (1993). All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood, 82, 2967–2974.
   PubMed Web of Science ®Google Scholar
• Kurzrock, R., Estey, E. and Talpaz, M. (1993). All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol, 11, 1489–1495.
   PubMed Web of Science ®Google Scholar
• Visani, G., Tosi, P., Manfroi, S., Ottaviani, E., Finelli, C., Cenacchi, A., Bendandi, M. and Tura, S. (1995). All-trans retinoic acid in the treatment of myelodysplastic syndromes. Leuk Lymphoma, 19, 277–280.
   PubMed Web of Science ®Google Scholar
• Negrin, R. S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J., Krantz, S. and Greenberg, P. L. (1993). Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood, 82, 737–743.
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg, E., Birgegard, G., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Merk, K., Tangen, J. M. and Winqvist, I. (1993). A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma, 11, 221–228.
   PubMed Web of Science ®Google Scholar
• Hansen, P. B., Johnsen, H. E., Hippe, E., Hellstrom-Lindberg, E. and Ralfkiaer, E. (1993). Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. Am J Hematol, 44, 229–236.
   PubMed Web of Science ®Google Scholar
• Verhoef, G., Demuynck, H., Zachee, P., Ceuppens, J., Dewitte, M. and Boogaerts, M. (1993). Treatment of myelodysplastic syndromes (MDS) with the combination of interleukin-3 and erythropoietin. Blood, 82(1), 377a.
   Google Scholar
• List, A. L., Noyes, W., Power, J., Thomas, T., Glinsmann-Gibson, B., Taetle, R., Miller-McCauley, V., Gross, M. and Miller, A. M. (1993). Combined treatment of myelodysplastic syndromes (MDS) with recombinant human interleukin-3 (IL-3) and erythropoietin (Epo). Blood, 82(1), 377a.
   Google Scholar
• Imamura, M., Kobayashi, M., Kobayashi, S., Yoshida, K., Mikuni, C., Ishikawa, Y., Matsumoto, S., Sakamaki, S., Niitsu, Y. and Hinoda, Y. (1994). Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol, 68, 163–166.
   PubMed Web of Science ®Google Scholar
• Nand, S., Sosman, J., Godwin, J. E. and Fisher, R. I. (1994). A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood, 83, 357–360.
   PubMed Web of Science ®Google Scholar
• Ho, A. D., Martin, H., Knauf, W., Reichardt, P., Trumper, L. and Hunstein, W. (1987). Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes. Leuk Res, 11, 1041–1044.
   PubMed Web of Science ®Google Scholar
• Clark, R. E., Ismail, S. A., Jacobs, A., Payne, H. and Smith, S. A. (1987). A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. Br J Haematol, 66, 77–83.
   PubMed Web of Science ®Google Scholar
• Hoelzer, D., Ganser, A., Ottmann, O. G., Hoffken, K., Becher, R., Lutz, D., Krieger, O., Diehl, V., Lathan, B. and Boogaerts, M. A. (1990). Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on leukemic blast cells in patients with myelodysplastic syndromes. Hematol Bluttransfus, 33, 763–769.
   PubMedGoogle Scholar
• Hoffken, K., Overkamp, F., Stirbu, J., Grothey, A., Flasshove, M., Hoelzer, D. and Ganser, A. (1990). Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study. Onkologie, 13, 33–37.
   PubMed Web of Science ®Google Scholar
• Keating, M. J., McCredie, K. B., Benjamin, R. S., Bodey, G. P., Zander, A., Smith, T. L. and Freireich, E. J. (1981). Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). Blood, 58, 584–591.
   PubMed Web of Science ®Google Scholar
• Michels, S. D., Saumur, J., Arthur, D. C., Robison, L. L. and Brunning, R. D. (1989). Refractory anemia with excess of blasts in transformation hematologic and clinical study of 52 patients. Cancer, 64, 2340–2346.
   PubMed Web of Science ®Google Scholar
• Hoyle, C. F., de Bastos, M., Wheatley, K., Sherrington, P. D., Fischer, P. J., Rees, J. K., Gray, R. and Hayhoe, F. G. (1989). AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol, 72, 45–53.
   PubMed Web of Science ®Google Scholar
• Gajewski, J. L., Ho, W. G., Nimer, S. D., Hirji, K. F., Gekelman, L., Jacobs, A. D. and Champlin, R. E. (1989). Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol, 7, 1637–1645.
   PubMed Web of Science ®Google Scholar
• Fenaux, P., Morel, P., Rose, C., Lai, J. L., Jouet, J. P. and Bauters, F. (1991). Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol, 77, 497–501.
   PubMed Web of Science ®Google Scholar
• Aul, C., Runde, V., Germing, U., Burk, M., Heyll, A., Hildebrandt, B. and Willers, R. (1995). Remission rates, survival and prognostic factors in 94 patients with advanced MDS treated with intensive chemotherapy. Ann Hematol, 70(2), A138.
   Google Scholar
• de Witte, T., Suciu, S., Peetermans, M., Fenaux, P., Strijckmans, P., Hayat, M., Jaksic, B., Selleslag, D., Zittoun, R. and Dardenne, M. (1995). Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia, 9, 1805–1811.
   PubMed Web of Science ®Google Scholar
• Estey, E. H., Kantarjian, H. M., O'Brien, S., Kornblau, S., Andreeff, M., Beran, M., Pierce, S. and Keating, M. (1995). High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther, 1, 21–28.
   PubMedGoogle Scholar
• Ganser, A., Heil, G., Hofmann, W. K., Ottmann, O. G., Seipelt, G., Fischer, J. Th., Langer, W., Brockhaus, W., Ittel, T. H., Brack, N., Knuth, A., Höffken, K., Klausmann, M., Fuhr, H. G., Bergmann, L. and Hoelzer, D. (1995). Aggressive chemotherapy with idarubicin, ARA-C, VP-16, amsacrin, followed by G-CSF and maintenance immunotherapy with interleukin-2 for advanced myelodysplastic syndromes and high-risk ANLL. Blood, 86, 434a.
   Web of Science ®Google Scholar
• Bernstein, S. H., Brunetto, V. L., Davey, F. R., Wurster-Hill, D., Mayer, R. J., Stone, R. M., Schiffer, C. A. and Bloomfield, C. D. (1996). Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol, 14, 2486–2494.
   PubMed Web of Science ®Google Scholar
• Gardin, C., Chaibi, P., de Revel, T., Rousselot, P., Turlure, P., Miclea, J. M., Nedellec, G. and Dombret, H. (1997). Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Reflexion en Hematologie. Leukemia, 11, 16–21.
   PubMed Web of Science ®Google Scholar